$ITW

Evercore ISI Adjusts PT on Illinois Tool Works to $309 From $272, Keeps Underperform Rating

Evercore ISI raised its price target on Illinois Tool Works to $309 from $272 and kept an Underperform rating, according to the firm. The article also notes Illinois Tool Works authorized a $6 billion share buyback and increased its dividend by 7% on Aug. 7.

Original reporting
Published Aug 11, 2026, 12:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 3:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ITW
Neutral
medium confidence
Mentioned
$ITW · $EVR
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ITWNeutralLow
01

Why it matters

For ITW, the actionable signal is the PT revision, but the unchanged rating implies the core risk/reward view is intact. Without new company fundamentals in the text, the trading impact is likely modest.

02

Market read

This is primarily a sell-side target update with no new operational or financial datapoint disclosed in the article body.

03

What to watch

Because the article lacks the underlying thesis or updated estimates, traders may discount the PT change versus any prior consensus and focus on upcoming company-specific catalysts (earnings, guidance, buyback execution).

Relevance 4/10Novelty 4/10Timing: today (analyst PT change reported pre-market)

Background

The piece is an analyst note summary: Evercore ISI adjusts Illinois Tool Works’ price target and reiterates an Underperform rating.

Company-level read

Ticker impact

$ITWNeutralMedium confidence
Context

Evercore ISI raised its price target on Illinois Tool Works to $309 from $272 while keeping an Underperform rating.

Expected impact

Likely mild support for ITW sentiment, but rating unchanged may cap upside follow-through.

Evidence & confidence

The only disclosed new item is the PT change; the article does not provide new fundamentals, guidance, or event-driven catalysts beyond the analyst action.

Market effects

Limited read-through to industrials; this is a single-name analyst target adjustment without sector-wide new data.

No clear regional spillover indicated.

No global macro or cross-border transaction details provided.

Counterpoint

The PT increase could reflect valuation math rather than improved earnings power, so the Underperform stance may still dominate positioning.

Key entities

  • Illinois Tool Works

    Subject of the analyst price-target adjustment and rating reiteration in the article.

  • Evercore ISI

    Broker/analyst issuing the PT change to $309 from $272 and keeping Underperform.

Related articles

$DELLHigh

Dell added to Evercore Tactical Outperform List ahead of earnings

Evercore ISI added Dell Technologies (NYSE:DELL) to its 'tactical outperform list' ahead of earnings, citing strong AI server demand and supply constraints. The firm expects a solid quarterly beat and raised fiscal 2027 guidance, with AI servers as the main growth driver. Street estimates project $44.9B revenue and $4.89 EPS, up 51% YoY. Dell's AI backlog stands at $51.3B, with supply constraints expected to persist.

Med

Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Antengene (6996.HK) presented R&D updates at the Evercore 2nd China Biotech Summit. Key highlights include Phase II data for ATG-022, showing ORR of 42.4% and 46.7% in two dose cohorts, and mOS of 12.85 months. The company also introduced its TriGager™ TCE platform and ATG-207, a bifunctional fusion protein. Antengene is advancing clinical trials for ATG-022 in gastric cancer and other indications.

$EVRMed

Everpure Jumps 6.0% After Guggenheim Maintains Buy

Everpure, Inc. shares rose 6.0% to $118.05 on Thursday on analyst upgrades and higher price targets, trading about 1.3M shares. Guggenheim kept a Buy and raised its target to $150. Citigroup raised to $118 (Buy), Evercore ISI to $120 (Outperform), Susquehanna to $120, and Morgan Stanley to $108 (Overweight). Average new target: $123.